Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into safe and effective applications that can have a meaningful impact on a patient’s health.
Our pipeline of novel microbiome modulators selectively increase the growth of beneficial bacteria in the colonic ecosystem and create a meaningful impact on a patient’s health. Our first therapy, RP-G28, is currently under development for the treatment of lactose intolerance and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. RP-G28 has been studied in a Phase 2 clinical trial and is a first-in-class compound.